Etidronate 200 mg daily was administered to four female patients with periodontitis and resultant alveolar pyorrhoea for periods of 2 weeks, followed by off-periods of 10 weeks or more, for 2–3 years. The macroscopic appearance of gingival mobility of the teeth, depth of periodontal pockets, and X-ray findings of alveolar bones improved markedly during this time. The effects were first observed after 6–12 months of treatment. These findings indicate that bisphosphonates may be effective in the treatment of periodontitis and resultant alveolar pyorrhoea. The effect may be mediated by the inhibitory action on bone resorption and the anti-inflammatory action of etidronate. Concomitant conventional dental management is also required.
CrippsS: Periodontal Disease: Recognition, Interception and Prevention.Chicago: Quintessence Publishing Co., 1984; p 21
2.
RiviereGRWeiszKSAdamsDFThomasDD: Pathogen-related oral spirochetes from dental plaques are invasive. Infect Immun1991; 59: 3377–3380
3.
KornmanKS: Controlled-release local delivery antimicrobials in periodontics: prospects for the future. J Periodontol1993; 64: 782–791
4.
JeffcoatMKReddyMS: Alveolar bone loss and osteoporosis: evidence for a common mode of therapy using the bisphosphonate alendronate. In: Biological Mechanisms of Tooth Movement and Craniofacial Adaptation (DavidovitchZNortonLA eds). Proceedings of the Second International Conference Held at Tara's Ferncroft Conference Resort, Danvers, MA, 19–22 Oct 1995. Boston: Harvard Society for the Advancement of Orthodontics, 1995; pp 365–373
5.
LindheJ: Textbook of Clinical Periodontology.Copenhagen: Munksgaard, 1983; p 298
6.
HarrisSTWattsNBJacksonRDGenantHKWasnichRDRossP: Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoprosis: three years of blinded therapy followed by one year of open therapy. Am J Med1993; 95: 557–567
7.
DunnCJFittonASorkinEM: Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging1994; 5: 446–474
8.
FleischH: Bisphosphonates in Bone Disease, 4th edn.San Diego: Academic Press, 2000; pp 182–206
9.
ReddyMSWeatherfordTWIIISmithCAWestBDJeffcoatMKJacksTM: Alendronate treatment of naturally occurring periodontitis in beagle dogs. J Periodontol1995; 66: 211–217
10.
ShojiKHoriuchiHShinodaH: Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodontal Res1995; 30: 277–284
11.
O'uchiNNishikawaHYoshinoTKanohHMotoieHNishimoriE: Inhibitory effects of YM175, a bisphosphonate, on the progression of experimental periodontitis in beagle dogs. J Periodontal Res1998; 33: 196–204
12.
Hiroi-FuruyaEKamedaTHiuraKManoHMiyazawaKNakamaruY: Etidronate (EHDP) inhibits osteoclastic bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int1999; 64: 219–223
13.
ReszkaAAHalasy-NagyJMMasarachiaPJRodanGA: Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst 1 kinase during apoptosis. A link between inhibition of the mevlonate pathway and regulation of an apoptosis promoting kinase. J Biol Chem1999; 274: 34967–34973
14.
JeffcoatMK: Osteoporosis: a possible modifying factor in oral bone loss. Ann Periodontol1998; 3: 312–321
15.
FrancisMDHovancikKBoyceRW: NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React1989; 11: 239–252
16.
PennanenNLapinjokiSUrttiAMonkkonenJ: Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res1995; 12: 916–922
17.
RussellRGRogersMJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone1999; 25: 97–106
